ClinicalTrials.gg
CompletedNCT03264651Updated Apr 18, 2018

Enobosarm and Anastrozole in Pre-menopausal Women With High Mammographic Breast Density

A Phase 1 interventional study of enobosarm in Mammographic Density, sponsored by Havah Therapeutics Pty Ltd. Completed at 1 site in Australia. Open to female participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2018-04-18.

Sponsored by Havah Therapeutics Pty Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Feb 2017, registered Aug 2017).
Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Female
01

Study summary

To evaluate the impact of a selective androgen receptor modulator combined with an aromatase inhibitor in reducing high mammographic breast density.

Read the detailed description

High mammographic breast density is a well recognized risk factor for the development of breast cancer and the masking of malignancy within the breast. Previous chemoprevention studies have revealed that only tamoxifen is efficacious in premenopausal women in the reduction of breast cancer. In order for this to occur mammographic density has to be reduced. Unfortunately the side effect profile of tamoxifen is such that not many women are taking up this therapeutic intervention. This trial is trying to establish a combination therapy to reduce mammographic breast density.

This phase 1 pilot study is combining oral enobosarm, a selective androgen receptor modulator, and oral anastrozole, an aromatase inhibitor, to study the impact of this combination treatment on mammographic breast density and breast elasticity. Safety and tolerability we also analyzed.

02

Conditions studied

  • Mammographic Density

Keywords

  • Selective androgen receptor modulator
  • Aromatase inhibitor
03

In context

Lead sponsor

Havah Therapeutics Pty Ltd is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of written
  • Pre-menopausal levels of FSH/LH/E2 (follicle stimulating hormone, luteinizing hormone, oestrogen) according to the definition of "pre-menopausal range" for the laboratory involved
  • Have a Volpara Density volumetric breast density of >15.5% (combined average both breasts)
  • Breast pain in the previous month of equal to or greater than 40mm on a 100mm visual analogue pain scale
  • WBC ≥ 3.0 x 109/L, granulocytes ≥ 1.5 X 109/L and ≥ 100 x 109/L.
  • /SGOT or ALT/SGPT ≤ 3 times
  • > 60 ml/min/1.73m2
  • Negative pregnancy test in women of (premenopausal or less than 12 months of amenorrhea , and who have not undergone surgical sterilization), no more than 7 days before the first dose of study treatment;
  • For women of childbearing potential who are sexually active, agreement to use a highly effective, non-hormonal form of during and for at least 6 months after completion of study treatment; OR, a fertile male partner willing and able to use effective non-hormonal means of contraception (barrier method of contraception in conjunction with spermicidal jelly, or surgical sterilization) during and for at least 6 months after completion of study treatment;

Exclusion criteria

Exclusion Criteria:

  • Presence of breast cancer
  • Diabetes mellitus or glucose intolerance defined as a fasting glucose >6mmol/l
  • Previous or concomitant other (non-breast cancer) within the previous 5 years (other than skin cancer)
  • History of coronary artery disease
  • Systemic hormonal
  • Risk of transmitting or viral hepatitis via infected blood
  • Known to any component of testosterone
  • Unable to comply with study requirements
  • Prolonged systemic treatment
  • Any drugs
  • Systemic hormone replacement therapy
  • Pregnant or lactating women
  • Known liver disease
  • Current warfarin usage
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    oral enobosarm and anastrozole

    9 mg of oral enbosarm and 1 mg of anastrozole daily

    Drug: enobosarm

Interventions

  • Oral combination therapy of enobosarm and anastrozole

    Also known as: anastrozole

This study also gives Anastrozole. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Mammographic breast density

    Volumetric analysis of fibroglandular density change on mammography utilizing Volpara software

    Time frame: 12 months

  2. Breast tissue elasticity

    Evaluation of breast elasticity change by direct shear wave ultrasonic measurement

    Time frame: 1 month

  3. Breast tissue elasticity

    Evaluation of breast elasticity change by direct shear wave ultrasonic measurement

    Time frame: 3 months

  4. Breast tissue elasticity

    Evaluation of breast elasticity change by direct shear wave ultrasonic measurement

    Time frame: 6 months

Secondary outcomes

  1. Breast pain scale

    Breast pain measured on a 100 mm visual analog scale

    Time frame: 1 month, 3 months, 12 months

  2. Serum gonadotropin levels

    serum follicular stimulating hormone and luteinizing hormone levels

    Time frame: 1 month, 3 months, 12 months

  3. Menopausal symptoms

    Menopause symptoms as recorded on a menopause symptoms scale

    Time frame: 3 months, 12 months

07

Study locations

1 site
  • Wellend Health
    Toorak Gardens, South Australia 5065, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 18, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03264651
Lead sponsor
Havah Therapeutics Pty Ltd
Collaborators
GTx
Responsible party
Sponsor
First posted
Aug 29, 2017
Start date
Feb 1, 2017
Primary completion
Mar 21, 2018
Completion
Mar 21, 2018
Last update
Apr 18, 2018

Study contacts

Stephen N Birrell, MD PhD
principal investigator · Havah Therapeutics Pty Ltd

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ostarine · Anastrozole

Start the discussion